Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz-Ares , Alexander Luft , David Vicente , Ali Tafreshi , Mahmut Gümüş , Julien Mazières , Barbara Hermes , Filiz Çay Şenler , Tibor Csőszi , Andrea Fülöp , Jerónimo Rodríguez-Cid , Jonathan Wilson , Shunichi Sugawara , Terufumi Kato , Ki Hyeong Lee , Ying Cheng , Luc Thiberville (1) , Silvia Novello , Balazs Halmos , Xiaodong Li , Gregory Lubiniecki , Bilal Piperdi , Dariusz Kowalski

1 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle

Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.

Domaines: Sciences du Vivant [q-bio]

Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, et al.. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379 (21), pp.2040-2051. ⟨10.1056/NEJMoa1810865⟩. ⟨hal-02345238⟩